Design And Performance Of Clinical Trials: An Overview
Webinar Details Title: Design and Performance of Clinical Trials: An Overview Date: Monday, October 20, 2014 Speaker:Anne Zajicek, MD, PharmD, FAAP, Chief, Obstetric and Pediatric, Pharmacology and Therapeutics Branch, National Institute of Child Health and Human...United States Pompe Community Update from Genzyme
Genzyme would like to share with you an important update regarding the recent United States (U.S.) Food and Drug Administration’s (FDA) approval of an expanded label for Lumizyme® (alglucosidase alfaA form of enzyme replacement therapy used to treat Pompe disease by...FDA and Genzyme Announce Label Expansion of Lumizyme in United States
To the United States Pompe Community: On August 1, 2014 the US Food and Drug Administration (FDA) and Genzyme issued press releases regarding the expansion of the Lumizyme® label (the enzyme replacement therapy for Pompe diseaseA rare genetic disease in which the body...2014 Helen Walker Research Grant Now Accepting Applications
The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe DiseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup tha... More research. This grant opportunity was made possible...BioMarin Doses First Patient in Phase 3 INSPIRE Trial with BMN 701 for the Treatment of Pompe
San Rafael, Calif., May 27, 2014 – BioMarin Pharmaceutical Inc. announced today that it has dosed the first patient with BMN 701 (GILT-tagged Recombinant Human GAA) in the Phase 3 INSPIRE trial for Pompe diseaseA rare genetic disease in which the body cannot properly...AMDA to Celebrate First International Pompe Day!!
Update: May 4, 2014 THE AMDA TO CELEBRATE THE FIRST INTERNATIONAL POMPE DAY WITH COMMEMORATIVE BOOK April 15, 2014 marked the International Pompe Association’s (IPA) first annual International Pompe Day. In honor of the First International Pompe Day, the Acid Maltase...